Department of Pharmacokinetics, Pfizer PGRD, Sandwich, Kent CT13 9NJ, UK.
J Comput Aided Mol Des. 2010 May;24(5):449-58. doi: 10.1007/s10822-010-9361-5. Epub 2010 May 9.
The results of a new method developed to identify well defined structural transformations that are key to improve a certain ADME profile are presented in this work. In particular Naïve Bayesian statistics and SciTegic FCFP_6 molecular fingerprints have been used to extract, from a dataset of 1,169 compounds with known in vitro UGT glucuronidation clearance, those changes in chemical structure that lead to a significant increase in this property. The effectiveness in achieving that goal of the thus found 55,987 transformations has been quantified and compared to classical medicinal chemistry transformations. The conclusion is that on average the new transformations found via in silico methods induce increases of UGT clearance by twofold, whilst the classical transformations are on average unable to alter that endpoint significantly in any direction. When both types of transformations are combined via substructural searches (SSS) the average twofold increase in glucuronidation is maintained. The implications of these findings for the drug design process are also discussed, in particular when compared to other methods previously described in the literature to address the question 'Which compound do I make next?'
本文介绍了一种新方法的研究结果,该方法旨在识别关键的结构转化,以改善特定的 ADME 特征。特别地,朴素贝叶斯统计学和 SciTegic FCFP_6 分子指纹已被用于从一个包含 1169 种已知体外 UGT 葡萄糖醛酸化清除率的化合物数据集提取导致该性质显著增加的化学结构变化。定量评估并比较了由此发现的 55987 种转化的实现目标的效果。结论是,平均而言,通过计算方法发现的新转化使 UGT 清除率提高了两倍,而经典的转化在任何方向上平均都无法显著改变该终点。当通过子结构搜索 (SSS) 组合这两种类型的转化时,葡萄糖醛酸化的平均两倍增加得以维持。还讨论了这些发现对药物设计过程的影响,特别是与文献中以前描述的其他方法相比,这些发现可以解决“我下一步应该合成哪种化合物?”这个问题。